Bevacizumab biosimilar candidate TAB008 compared to Avastin® in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study-Reference-Cited by-同舟云学术

Bevacizumab biosimilar candidate TAB008 compared to Avastin® in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study

Published:2023-01-03 Issue:9 Volume:149 Page:5907-5914
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Lu S.,Qin S.,Zhou Z.,Chen J.,Gu K.,Sun P.,Pan Y.,Yu G.,Ma K.,Shi J.,Sun Y.,Yang L.,Chen P.,Liu A.,He J.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-04563-4.pdf

Reference13 articles.

1. AVASTIN.FDA approval Package Insert. 06/2019

2. Finn RS, Qin S, Ikeda M, Galle PR, IMbrave150 Investigators et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894–1905

3. Fukuoka M, Wu YL, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866–2874

4. Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL (2020) Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017

5. He K, Chen H, Gwise T, Casak S, Lemery S, Keegan P, Pazdur R, Sridhara R (2016) Statistical considerations in evaluating a biosimilar product in an oncology clinical study. Clin Cancer Res 22(21):5167–5170

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China;JAMA Network Open;2023-10-12